Imago BioSciences, Inc. presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in a poster presentation session during the 64thAmerican Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022. A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30thEuropean Hematology Association Annual Meeting and congress (EHA) in June 2022.

Updated Highlights (available data as of 18 October 2022): Of evaluable patients at 24 weeks: 65% (17/26) showed a decrease in Total Symptom Score (TSS). 19% (5/26) showed a = 50% decrease in TSS. 66% (33/50) showed spleen volume reductions from baseline.

28% (14/50) showed a = 20% spleen volume reduction. The majority of patients had a decrease in mutant allele frequencies (MAF) including driver mutations (e.g., JAK2) and high molecular risk (HMR) mutations (e.g., ASXL1). 90% (37/41) of transfusion-independent patients had stable (19/41) or improved (18/41) hemoglobin at Week 12.

85% (50/59) of patients had an improved (19/59) or stable (31/59) bone marrow fibrosis score post-baseline. No new mutations or transformations to acute myeloid leukemia (AML) while on treatment, even in patients with a high-risk of progression. Safety and Tolerability Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis.

The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 33% (30/90) of patients and led to discontinuation of the study in 1 patient. There were 44 patients who reported a total of 86 serious adverse events (SAEs), 16% of which were deemed drug-related by the investigator.